Patient-reported health preferences of anticoagulant-related outcomes

Ye Wang, Feng Xie, Ming Chai Kong, Lai Heng Lee, Heng Joo Ng, Yu Ko

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 % among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume40
Issue number3
DOIs
Publication statusPublished - Oct 24 2015

Fingerprint

Anticoagulants
Health
Warfarin
Stroke
Visual Analog Scale
Intracranial Hemorrhages
Quality of Life
Patient Preference
Cost-Benefit Analysis
Cross-Sectional Studies
Dabigatran
Rivaroxaban

Keywords

  • Anticoagulant
  • Preference
  • Stroke
  • Utility
  • Warfarin

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Patient-reported health preferences of anticoagulant-related outcomes. / Wang, Ye; Xie, Feng; Kong, Ming Chai; Lee, Lai Heng; Ng, Heng Joo; Ko, Yu.

In: Journal of Thrombosis and Thrombolysis, Vol. 40, No. 3, 24.10.2015, p. 268-273.

Research output: Contribution to journalArticle

Wang, Ye ; Xie, Feng ; Kong, Ming Chai ; Lee, Lai Heng ; Ng, Heng Joo ; Ko, Yu. / Patient-reported health preferences of anticoagulant-related outcomes. In: Journal of Thrombosis and Thrombolysis. 2015 ; Vol. 40, No. 3. pp. 268-273.
@article{2e6e96de0748423f9771125bb9bb3da4,
title = "Patient-reported health preferences of anticoagulant-related outcomes",
abstract = "Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 {\%} among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.",
keywords = "Anticoagulant, Preference, Stroke, Utility, Warfarin",
author = "Ye Wang and Feng Xie and Kong, {Ming Chai} and Lee, {Lai Heng} and Ng, {Heng Joo} and Yu Ko",
year = "2015",
month = "10",
day = "24",
doi = "10.1007/s11239-015-1191-9",
language = "English",
volume = "40",
pages = "268--273",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Patient-reported health preferences of anticoagulant-related outcomes

AU - Wang, Ye

AU - Xie, Feng

AU - Kong, Ming Chai

AU - Lee, Lai Heng

AU - Ng, Heng Joo

AU - Ko, Yu

PY - 2015/10/24

Y1 - 2015/10/24

N2 - Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 % among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.

AB - Strokes can have a catastrophic impact on patients’ health-related quality of life (HRQoL). In addition to warfarin, two novel oral anticoagulants, i.e., dabigatran and rivaroxaban, have been approved to prevent strokes. This study aimed to use direct measures to elicit patient-reported utilities (i.e., preferences) for anticoagulant-related outcomes. A cross-sectional survey was administered to 100 patients taking warfarin in an anticoagulation clinic. Utilities for six long-term and four short-term anticoagulant-related health states were elicited by the visual analogue scale (VAS) and standard gamble (SG) methods. Health states with the highest SG-derived mean utility values were “well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 ± 0.17), and “well on dabigatran” (0.83 ± 0.18). Approximately half of the patients considered major ischemic stroke (−1.57 ± 6.77) and intracranial hemorrhage (−1.99 ± 6.98) to be worse than death. The percentages of patients who considered a particular health state worse than death ranged from 0 to 55 % among various health states assessed. The VAS had similar findings. Good logical consistency was observed in both VAS- and SG-derived utility values. Ischemic stroke and intracranial hemorrhage had a significant impact on patients’ HRQoL. Greater variation in patients’ preferences was observed for more severely impaired health states, indicating the need for individualized medical decision-making. In this study, both long-term and short-term health states were included in the utility assessment. The findings of this study can be used in cost-utility analysis of future anticoagulation therapies.

KW - Anticoagulant

KW - Preference

KW - Stroke

KW - Utility

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84940440115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940440115&partnerID=8YFLogxK

U2 - 10.1007/s11239-015-1191-9

DO - 10.1007/s11239-015-1191-9

M3 - Article

VL - 40

SP - 268

EP - 273

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 3

ER -